Page 9 - Mark Enyedy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The cancer-fighting specialist's new antibody treatment could be a gamechanger.

Press release content from Business Wire. The AP news staff was not involved in its creation.

IMGN earnings call for the period ending September 30, 2021.

Follow John on: FTSE 100 lower with Scottish Mortgage trust leading the retreat; Wall Street mixed as Dow crosses 35K Tech shares appear to be out of fashion this week, as the US Nasdaq gave up more than 1% The FTSE 100 down 6 points Tech stocks out of favour Centricafriendless after downbeat trading update 12.05pm: Major diversion among US indices as midday The FTSE 100 ended down 6 points at 7,124, while the FTSE 250 lost 78 points, 0.3%, to close at 22,697. "Sterling traders seem unperturbed by the prospect of the UK economy moving into another period of political uncertainty, as the ele...

Mark Enyedy is currently chief executive of Nasdaq-listed ImmunoGen There will be a new face around the Ergomed boardroom table Growing pharma services group Ergomed PLC (LON:ERGO) has appointed Mark Enyedy as its new independent director. Currently chief executive of Nasdaq-listed ImmunoGen, he was formerly head of corporate development for Shire where he oversaw the acquisitions of NPS Pharmaceuticals and Dyax Corp along with its US$32bn combination with Baxalta. Ergomed chairman, Dr Miroslav Reljanović, said: "Mark has extensive corporate development experience in the US, UK a...